Vinicio A De Jesus Perez

List of Publications by Year
in descending order

115 papers	4,528 citations	109137 35 h-index	110170 64 g-index
252 all docs	252 docs citations	252 times ranked	5470 citing authors

#	Article	IF	Citations
1	FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. Journal of Clinical Investigation, 2013, 123, 3600-3613.	3.9	354
2	Pulmonary Arterial Hypertension Is Linked to Insulin Resistance and Reversed by Peroxisome Proliferatorâ€“Activated Receptor-Î³ Activation. Circulation, 2007, 115, 1275-1284.	1.6	344
3	An antiproliferative BMP-2/PPARÎ³/apoE axis in human and murine SMCs and its role in pulmonary hypertension. Journal of Clinical Investigation, 2008, 118, 1846-1857.	3.9	314
4	Disruption of PPARÎ³/Î²-cateninâ€“mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. Journal of Clinical Investigation, 2011, 121, 3735-3746.	3.9	217
5	Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wntâ€“Î²-catenin and Wntâ€“RhoAâ€“Rac1 pathways. Journal of Cell Biology, 2009, 184, 83-99.	2.3	194
6	A Unique Collateral Artery Development Program Promotes Neonatal Heart Regeneration. Cell, 2019, 176, 1128-1142.e18.	13.5	162
7	Disruption of the Apelin-APJ System Worsens Hypoxia-Induced Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 814-820.	1.1	148
8	Reduced BMPR2 expression induces GM-CSF translation and macrophage recruitment in humans and mice to exacerbate pulmonary hypertension. Journal of Experimental Medicine, 2014, 211, 263-280.	4.2	123
9	MiR-133a Modulates Osteogenic Differentiation of Vascular Smooth Muscle Cells. Endocrinology, 2013, 154, 3344-3352.	1.4	119
10	Endothelial dysfunction in pulmonary arterial hypertension: an evolving landscape (2017 Grover) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3	0.8	115
11	The 6th World Symposium on Pulmonary Hypertension: whatâ€™s old is new. F1000Research, 2019, 8, 888.	0.8	93
12	Loss of Endothelium-Derived Wnt5a Is Associated With Reduced Pericyte Recruitment and Small Vessel Loss in Pulmonary Arterial Hypertension. Circulation, 2019, 139, 1710-1724.	1.6	90
13	Features and Outcomes of Methamphetamine-associated Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 788-800.	2.5	81
14	S100A4 and Bone Morphogenetic Protein-2 Codependently Induce Vascular Smooth Muscle Cell Migration via Phosphoâ€“Extracellular Signal-Regulated Kinase and Chloride Intracellular Channel 4. Circulation Research, 2009, 105, 639-647.	2.0	80
15	Whole-Exome Sequencing Reveals TopBP1 as a Novel Gene in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1260-1272.	2.5	70
16	Loss of Bone Morphogenetic Protein Receptor 2 Is Associated with Abnormal DNA Repair in Pulmonary Arterial Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2014, 50, 1118-1128.	1.4	70
17	Hydrogel-based delivery of Il-10 improves treatment of bleomycin-induced lung fibrosis in mice. Biomaterials, 2019, 203, 52-62.	5.7	69
18	New and Emerging Therapies for Pulmonary Arterial Hypertension. Annual Review of Medicine, 2019, 70, 45-59.	5.0	68

#	Article	IF	Citations
19	BMP promotes motility and represses growth of smooth muscle cells by activation of tandem Wnt pathways. Journal of Cell Biology, 2011, 192, 171-188.	2.3	64
20	Activation of the Wnt/Planar Cell Polarity Pathway Is Required for Pericyte Recruitment during Pulmonary Angiogenesis. American Journal of Pathology, 2015, 185, 69-84.	1.9	60
21	Interleukinâ€10â€“mediated regenerative postnatal tissue repair is dependent on regulation of hyaluronan metabolismviafibroblastâ€specific STAT3 signaling. FASEB Journal, 2017, 31, 868-881.	0.2	59
22	Outpatient Inhaled Nitric Oxide in a Patient with Vasoreactive Idiopathic Pulmonary Arterial Hypertension and COVID-19 Infection. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 130-132.	2.5	56
23	Current Clinical Management of Pulmonary Arterial Hypertension. Circulation Research, 2014, 115, 131-147.	2.0	55
24	Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 148-157.	2.5	53
25	Emerging role of angiogenesis in adaptive and maladaptive right ventricular remodeling in pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 314, L443-L460.	1.3	51
26	<scp>PDGF</scp>â€dependent Î²â€catenin activation is associated with abnormal pulmonary artery smooth muscle cell proliferation in pulmonary arterial hypertension. FEBS Letters, 2016, 590, 101-109.	1.3	46
27	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective. Nature Reviews Cardiology, 2022, 19, 314-331.	6.1	46
28	Molecular pathogenesis and current pathology of pulmonary hypertension. Heart Failure Reviews, 2016, 21, 239-257.	1.7	45
29	Long Noncoding RNA TYKRIL Plays a Role in Pulmonary Hypertension via the p53-mediated Regulation of PDGFRÎ². American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1445-1457.	2.5	45
30	Right Heart Score for Predicting Outcome in Idiopathic, Familial, or Drug- and Toxin-Associated Pulmonary Arterial Hypertension. JACC: Cardiovascular Imaging, 2015, 8, 627-638.	2.3	44
31	Suppression of endothelial CD39/ENTPD1 is associated with pulmonary vascular remodeling in pulmonary arterial hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 308, L1046-L1057.	1.3	43
32	Targeting the Wnt signaling pathways in pulmonary arterial hypertension. Drug Discovery Today, 2014, 19, 1270-1276.	3.2	41
33	Codependence of Bone Morphogenetic Protein Receptor 2 and Transforming Growth Factor-Î² in Elastic Fiber Assembly and Its Perturbation in Pulmonary Arterial Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1559-1569.	1.1	41
34	Oxido-reductive regulation of vascular remodeling by receptor tyrosine kinase ROS1. Journal of Clinical Investigation, 2014, 124, 5159-5174.	3.9	38
35	Diagnosis and Management of Pulmonary Hypertension in the Modern Era: Insights from the 6th World Symposium. Pulmonary Therapy, 2020, 6, 9-22.	1.1	38
36	Effectiveness of YouTube as a Source of Medical Information on Heart Transplantation. Interactive Journal of Medical Research, 2013, 2, e28.	0.6	38

#	Article	IF	Citations
37	Health Disparities in Patients with Pulmonary Arterial Hypertension: A Blueprint for Action. An Official American Thoracic Society Statement. American Journal of Respiratory and Critical Care Medicine, 2017, 196, e32-e47.	2.5	36
38	Increased Pyruvate Dehydrogenase Kinase 4 Expression in Lung Pericytes Is Associated with Reduced Endothelial-Pericyte Interactions and Small Vessel Loss in Pulmonary Arterial Hypertension. American Journal of Pathology, 2016, 186, 2500-2514.	1.9	35
39	Reduced carboxylesterase 1 is associated with endothelial injury in methamphetamine-induced pulmonary arterial hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 313, L252-L266.	1.3	35
40	Mechanics of right ventricular dysfunction in pulmonary arterial hypertension and heart failure with preserved ejection fraction. Cardiovascular Diagnosis and Therapy, 2020, 10, 1580-1603.	0.7	35
41	Loss of Adenomatous Poliposis Coli-Î±3 Integrin Interaction Promotes Endothelial Apoptosis in Mice and Humans. Circulation Research, 2012, 111, 1551-1564.	2.0	34
42	Safety and Efficacy of Transition from Systemic Prostanoids to Inhaled Treprostinil in Pulmonary Arterial Hypertension. American Journal of Cardiology, 2012, 110, 1546-1550.	0.7	34
43	Angina Associated With Left Main Coronary Artery Compression in Pulmonary Hypertension. Journal of Heart and Lung Transplantation, 2009, 28, 527-530.	0.3	32
44	Loss of PPARÎ³ in endothelial cells leads to impaired angiogenesis. Journal of Cell Science, 2016, 129, 693-705.	1.2	32
45	Drug-induced pulmonary arterial hypertension: a primer for clinicians and scientists. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 314, L967-L983.	1.3	32
46	Novel Signaling Pathways in Pulmonary Arterial Hypertension (2015 Grover Conference Series). Pulmonary Circulation, 2016, 6, 285-294.	0.8	31
47	Portopulmonary Hypertension: From Bench to Bedside. Frontiers in Medicine, 2020, 7, 569413.	1.2	31
48	Perlecan heparan sulfate deficiency impairs pulmonary vascular development and attenuates hypoxic pulmonary hypertension. Cardiovascular Research, 2015, 107, 20-31.	1.8	30
49	Modified High-Molecular-Weight Hyaluronan Promotes Allergen-Specific Immune Tolerance. American Journal of Respiratory Cell and Molecular Biology, 2017, 56, 109-120.	1.4	30
50	Perioperative Pharmacological Management of Pulmonary Hypertensive Crisis during Congenital Heart Surgery. Pulmonary Circulation, 2014, 4, 10-24.	0.8	29
51	Mural Cell SDF1 Signaling Is Associated with the Pathogenesis of Pulmonary Arterial Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2020, 62, 747-759.	1.4	29
52	Methamphetamine and the risk of pulmonary arterial hypertension. Current Opinion in Pulmonary Medicine, 2018, 24, 416-424.	1.2	28
53	Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry. Annals of the American Thoracic Society, 2021, 18, 613-622.	1.5	27
54	Diagnosis and Management of Pulmonary Hypertension Associated with Left Ventricular Diastolic Dysfunction. Pulmonary Circulation, 2012, 2, 163-169.	0.8	23

#	Article	IF	Citations
55	Tie2-dependent VHL knockdown promotes airway microvascular regeneration and attenuates invasive growth of Aspergillus fumigatus. Journal of Molecular Medicine, 2013, 91, 1081-1093.	1.7	22
56	Prioritizing Equity and Diversity in Academic Medicine Faculty Recruitment and Retention. JAMA Health Forum, 2021, 2, e212426.	1.0	22
57	Distinct types of plexiform lesions identified by synchrotron-based phase-contrast micro-CT. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L17-L28.	1.3	19
58	Lung Pericytes in Pulmonary Vascular Physiology and Pathophysiology. , 2021, 11, 2227-2247.		19
59	MicroRNAs: promising therapeutic targets for the treatment of pulmonary arterial hypertension. Expert Opinion on Therapeutic Targets, 2013, 17, 557-564.	1.5	18
60	Genetic Admixture and Survival in Diverse Populations with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1407-1415.	2.5	18
61	Coexistence of primary adenocarcinoma of the lung and Tsukamurella infection: a case report and review of the literature. Journal of Medical Case Reports, 2008, 2, 207.	0.4	17
62	Systemic hypoxia led to little retinal neuronal loss and dramatic optic nerve glial response. Experimental Eye Research, 2020, 193, 107957.	1.2	17
63	Targeted proteomics of right heart adaptation to pulmonary arterial hypertension. European Respiratory Journal, 2021, 57, 2002428.	3.1	16
64	Novel Mechanisms Targeted by Drug Trials in Pulmonary Arterial Hypertension. Chest, 2022, 161, 1060-1072.	0.4	16
65	The Intersection of Genes and Environment. Chest, 2012, 141, 1598-1600.	0.4	15
66	Recent advances in the management of pulmonary arterial hypertension. F1000Research, 2016, 5, 2755.	0.8	15
67	Cyclosporine Does Not Prevent Microvascular Loss in Transplantation but Can Synergize With a Neutrophil Elastase Inhibitor, Elafin, to Maintain Graft Perfusion During Acute Rejection. American Journal of Transplantation, 2015, 15, 1768-1781.	2.6	14
68	Novel TNIP2 and TRAF2 Variants Are Implicated in the Pathogenesis of Pulmonary Arterial Hypertension. Frontiers in Medicine, 2021, 8, 625763.	1.2	13
69	Low-grade albuminuria in pulmonary arterial hypertension. Pulmonary Circulation, 2019, 9, 204589401882456.	0.8	11
70	Methamphetamine use association with pulmonary diseases: a retrospective investigation of hospital discharges in California from 2005 to 2011. ERJ Open Research, 2019, 5, 00017-2019.	1.1	7
71	MicroRNA and Cardiovascular Disease. BioMed Research International, 2015, 2015, 1-2.	0.9	6
72	In Vivo Study of Human Endothelial-Pericyte Interaction Using the Matrix Gel Plug Assay in Mouse. Journal of Visualized Experiments, 2016, , .	0.2	6

#	Article	IF	Citations
73	Novel approaches to pulmonary arterial hypertension drug discovery. Expert Opinion on Drug Discovery, 2016, 11, 407-414.	2.5	6
74	Career Development of Young Physicianâ€“Scientists in the Cardiovascular Sciences. Circulation Research, 2018, 122, 1330-1333.	2.0	6
75	Hypoxia-induced inflammation: Profiling the first 24-hour posthypoxic plasma and central nervous system changes. PLoS ONE, 2021, 16, e0246681.	1.1	6
76	Pulmonary Arterial Hypertension Secondary to Drugs and Toxins. Clinics in Chest Medicine, 2021, 42, 19-38.	0.8	6
77	Perspectives on Cardiopulmonary Critical Care for Patients With COVIDâ€19: From Members of the American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation. Journal of the American Heart Association, 2020, 9, e017111.	1.6	5
78	The cancer hypothesis of pulmonary arterial hypertension: the next ten years. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 318, L1138-L1139.	1.3	5
79	Anatomic, genetic and functional properties of the retinal circulation in pulmonary hypertension. Pulmonary Circulation, 2020, 10, 1-4.	0.8	5
80	Puerto Rico Health System Resilience After Hurricane Maria: Implications for Disaster Preparedness in the COVID-19 Era. Frontiers in Communication, 2021, 5, .	0.6	5
81	Health Disparities in Pulmonary Arterial Hypertension and the Impact of the COVID-19 Pandemic. Advances in Pulmonary Hypertension, 2021, 20, 6-15.	0.1	5
82	Pumping It Up! Angiogenesis and Muscle Deconditioning in Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 250-251.	2.5	5
83	A Case of Recurrent Pericardial Constriction Presenting with Severe Pulmonary Hypertension. Pulmonary Circulation, 2013, 3, 436-439.	0.8	4
84	Stimulants and Pulmonary Arterial Hypertension: An Update. Advances in Pulmonary Hypertension, 2018, 17, 49-54.	0.1	4
85	Pulmonary Vein Stenosis and Pulmonary Hypertension Following a Catheter-Based Radiofrequency Ablation for Atrial Fibrillation: A Case Report. American Journal of Case Reports, 2020, 21, e924709.	0.3	4
86	Understanding the Pharmacokinetics of Oral Treprostinil in Patients With Pulmonary Arterial Hypertension. Journal of Cardiovascular Pharmacology, 2013, 61, 471-473.	0.8	3
87	Clinical outcomes of inferior vena cava filter in complicated pulmonary embolism. Pulmonary Circulation, 2019, 9, 1-10.	0.8	3
88	In Defense of the Nucleus: NUDT1 and Oxidative DNA Damage in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 541-542.	2.5	3
89	Immunoprofiling of Nonarteritic Anterior Ischemic Optic Neuropathy. Translational Vision Science and Technology, 2021, 10, 17.	1.1	3
90	Drug-Induced Pulmonary Hypertension: The First 50 Years. Advances in Pulmonary Hypertension, 2017, 15, 133-137.	0.1	3

#	Article	IF	Citations
91	Long-Term Right Ventricular Adaptation to Postnatal Hyperoxia: Too Much of a Good Thing?. American Journal of Respiratory Cell and Molecular Biology, 2017, 56, 559-560.	1.4	2
92	MicroRNA and Cardiovascular Disease 2016. BioMed Research International, 2017, 2017, 1-2.	0.9	2
93	EMAPII: A Key Player in HIV-Nefâ€“induced Pulmonary Vasculopathy. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 257-258.	1.4	2
94	Hiding in Plain Sight: The Basement Membrane in Pulmonary Vascular Remodeling. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 13-14.	1.4	2
95	Drug- and toxin-induced pulmonary arterial hypertension: Current state of the literature. Global Cardiology Science & Practice, 2020, 2019, .	0.3	2
96	Optical Coherence Tomography of Pulmonary Arterial Walls in Humans and Pigs (Sus scrofa) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 542 T	0.4	2
97	Health disparity is a global issue: Understanding Latin America. Pulmonary Circulation, 2022, 12, e12049.	0.8	2
98	An evidence appraisal of heart organoids in a dish and commensurability to human heart development in vivo. BMC Cardiovascular Disorders, 2022, 22, 122.	0.7	2
99	Hispanic Ethnicity and Social Determinants of Health: Harnessing Data from The Pulmonary Hypertension Association Registry. Advances in Pulmonary Hypertension, 2022, 21, 44-48.	0.1	2
100	Pulmonary Vascular Complications of Liver Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 198, P5-P6.	2.5	1
101	EpiHope for the Treatment of Pulmonary Arterial Hypertension: Selective versus Nonselective BET Inhibition. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1188-1190.	2.5	1
102	Prescription Patterns for Pulmonary Vasodilators in the Treatment of Pulmonary Hypertension Associated With Chronic Lung Diseases: Insights From a Clinician Survey. Frontiers in Medicine, 2021, 8, 764815.	1.2	1
103	First among Equals: Nerve Growth Factor in the Pathogenesis of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 274-275.	2.5	0
104	Inducible pluripotent stem cells and pulmonary arterial hypertension: the future is now!. Stem Cell Investigation, 2017, 4, 53-53.	1.3	0
105	Myocardial bridge: an unrecognized cause of chest pain in pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-4.	0.8	0
106	No Good Deed Goes Unpunished. Chest, 2021, 159, 910-911.	0.4	0
107	CHK yourself, before you wreck yourself: targeting the DNA damage response in secondary pulmonary hypertension. Thorax, 2022, 77, 218-219.	2.7	0
108	Development of a recurrent pleural effusion in a patient with pulmonary arterial hypertension treated with imatinib. Case Reports in Clinical Medicine, 2012, 01, 38-41.	0.1	0

#	Article	IF	Citations
109	Special Considerations for the Pulmonary Hypertension Patient. , 2016, , 345-358.		0
110	Editorial: Pulmonary Hypertension in the Modern Era: Science and Clinical Practice. Frontiers in Medicine, 2021, 8, 785181.	1.2	0
111	Gender and Race Disparities in Pulmonary Hypertension Diagnosis and Treatment. Respiratory Medicine, 2020, , 195-202.	0.1	0
112	Abstract 15092: The Yin-yang of Bmpr2 and Ces1 in the Pulmonary Endothelium Aad Its Role in Pulmonary Arterial Hypertension. Circulation, 2020, 142, .	1.6	0
113	Abstract 15053: Vascular Inflammation in Pulmonary Hypertension is Exacerbated by Litaf-dependent Pericyte Signaling. Circulation, 2020, 142, .	1.6	0
114	Guest Editors' Memo: Disparities in Pulmonary Arterial Hypertension Care: Challenges and Solutions. Advances in Pulmonary Hypertension, 2022, 21, 29-29.	0.1	0
115	Wnt Signaling Interactor WTIP (Wilms Tumor Interacting Protein) Underlies Novel Mechanism for Cardiac Hypertrophy. Circulation Genomic and Precision Medicine, 0, , .	1.6	0